V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 330003356 | 330001742 | null | null | Curative (C) | 2014-10-16 | 2014-10-18 | EW EuroEwing 2012 Arm A VIDE | N | N | 330012689 | EURO-EWING |
| 330003357 | 330001743 | 1.6 | 50 | Curative (C) | 2015-10-22 | 2015-10-22 | CETUXIMAB | 02 | N | 330012690 | CETUXIMAB |
| 330003358 | 330001744 | 1.78 | 97.5 | Curative (C) | 2014-02-24 | 2014-03-04 | Cetuximab + Radiotherapy Load | 2 | N | 330012692 | CETUXIMAB + RT |
| 330003359 | 330001745 | null | 50 | Curative (C) | 2015-05-06 | 2015-05-18 | Cisplatin + Etoposide (5 day) | null | N | 330012693 | CISPLATIN + ETOPOSIDE |
| 330003360 | 330001745 | 1.71 | 54 | Curative (C) | null | 2015-10-28 | CETUXIMAB + RT | N | Y | 330012693 | CETUXIMAB + RT |
| 330003361 | 330001745 | 1.55 | 58 | Curative (C) | null | 2017-09-03 | Cetuximab 7 day (Cycle 1) | N | Y | 330012693 | CETUXIMAB |
| 330003362 | 330001745 | 1.51 | 28.6 | Palliative (P) | 2016-12-11 | 2016-12-15 | GEMCARBO | 02 | N | 330012693 | GEMCARBO |
| 330003363 | 330012164 | 1.52 | 61.7 | Palliative (P) | null | 2014-05-04 | CETUXIMAB | null | null | 330012702 | CETUXIMAB |
| 330003364 | 330012651 | 1.58 | 19.9 | Disease modification (D) | 2014-08-30 | 2014-09-02 | CYCLOPHOSPHAMIDE + RITUXIMAB | 02 | null | 330012705 | CYCLOPHOSPHAMIDE + RITUXIMAB |
| 330003365 | 330012651 | 1.64 | 44.4 | Curative (C) | 2014-10-09 | 2014-12-03 | EW EuroEwing 99 : VIDE | N | N | 330012705 | EURO-EWING |
| 330003366 | 330001746 | 1.7 | 96 | Curative (C) | 2016-08-04 | 2016-08-06 | DA 3 + 10 | N | N | 330012707 | DA |
| 330003367 | 330001746 | 1.65 | 64.6 | Curative (C) | null | 2016-01-06 | CETUXIMAB + RT | Y | Y | 330012707 | CETUXIMAB + RT |
| 330003368 | 330001746 | 1.53 | 62.6 | Curative (C) | 2014-09-24 | 2014-09-30 | CYCLOPHOSPHAMIDE + RITUXIMAB | 2 | N | 330012707 | CYCLOPHOSPHAMIDE + RITUXIMAB |
| 330003369 | 330001747 | 1.64 | 48.6 | null | 2016-12-05 | 2016-12-26 | Cetuximab + Radiotherapy Load | 02 | N | 330012711 | CETUXIMAB + RT |
| 330003370 | 330001748 | 1.64 | 67 | Disease modification (D) | 2016-04-12 | 2016-04-13 | CVP R | N | N | 330012712 | CVP R |
| 330003371 | 330001748 | 1.58 | 53.4 | Curative (C) | 2013-05-26 | 2013-06-05 | OST Euramos 1 Closed Trial - AP | N | N | 330012712 | MAP |
| 330003372 | 330001749 | 1.85 | 66.8 | Neo-adjuvant (N) | 2015-03-14 | 2015-03-15 | Cisplatin + Etoposide (3 day) | N | N | 330012715 | CISPLATIN + ETOPOSIDE |
| 330003373 | 330001749 | 1.69 | 82.95 | Disease modification (D) | 2014-01-11 | 2014-02-15 | CYCLOPHOSPHAMIDE + RITUXIMAB | 02 | Y | 330012715 | CYCLOPHOSPHAMIDE + RITUXIMAB |
| 330003374 | 330001749 | 0 | 89.9 | Neo-adjuvant (N) | 2013-03-21 | 2013-03-27 | Carbo F | N | N | 330012715 | CARBO + FLUOROURACIL |
| 330003375 | 330001750 | 1.81 | 47.8 | Palliative (P) | 2017-12-22 | 2018-01-09 | CYCLOPHOSPHAMIDE + RITUXIMAB | 02 | N | 330012721 | CYCLOPHOSPHAMIDE + RITUXIMAB |
| 330003376 | 330001750 | 1.7 | 57.2 | Palliative (P) | 2015-12-07 | 2015-12-19 | Cisplatin + Etoposide (3 day) | 2 | N | 330012721 | CISPLATIN + ETOPOSIDE |
| 330003377 | 330001750 | 1.67 | 32 | Curative (C) | 2013-05-15 | 2013-05-16 | DA | 02 | N | 330012721 | DA |
| 330003378 | 330001750 | 1.81 | 73.1 | Curative (C) | 2017-08-12 | 2017-08-26 | Cetuximab 7 day (Cycle 1) | N | Y | 330012721 | CETUXIMAB |
| 330003379 | 330001751 | 1.84 | 57 | Curative (C) | 2014-02-08 | 2014-02-11 | MAP | Y | N | 330012730 | MAP |
| 330003380 | 330001751 | 1.65 | 42.4 | Palliative (P) | null | 2016-07-24 | CETUXIMAB | N | Y | 330012730 | CETUXIMAB |
| 330003381 | 330001751 | 0 | 9.2 | Curative (C) | 2015-03-24 | 2015-04-09 | Dox + HD Mtx (post PAM) | N | N | 330012730 | DOXORUBICIN + HD MTX |
| 330003382 | 330011304 | 1.61 | 106.3 | Palliative (P) | 2016-09-03 | 2016-09-05 | CAP | N | N | 330012736 | CAP |
| 330003383 | 330011304 | 1.78 | 78 | Adjuvant (A) | 2016-09-14 | 2016-09-21 | CAP | null | null | 330012736 | CAP |
| 330003384 | 330011304 | 1.66 | 74 | Adjuvant (A) | 2013-09-27 | 2013-09-27 | CAP | 02 | N | 330012736 | CAP |
| 330003386 | 330001753 | null | 53.5 | Neo-adjuvant (N) | 2017-06-29 | 2017-07-02 | Dox + HD Mtx (post PAM) | N | N | 330012744 | DOXORUBICIN + HD MTX |
| 330003387 | 330001754 | 1.96 | 62.4 | null | 2017-05-06 | 2017-05-09 | CARBO + FLUOROURACIL | N | null | 330012747 | CARBO + FLUOROURACIL |
| 330003389 | 330006938 | 1.6 | 42.3 | Curative (C) | null | 2018-04-05 | CETUXIMAB + RT | null | null | 330012751 | CETUXIMAB + RT |
| 330003390 | 330006938 | 1.63 | 54.8 | Curative (C) | 2015-07-28 | 2015-07-29 | CETUXIMAB + RT | 2 | null | 330012751 | CETUXIMAB + RT |
| 330003391 | 330011305 | 0 | 67.2 | Neo-adjuvant (N) | 2013-02-04 | 2013-02-04 | OST Euramos 1 Closed Trial - AP | 02 | N | 330012756 | MAP |
| 330003392 | 330001756 | 1.68 | 121.7 | Curative (C) | 2013-07-01 | 2013-07-02 | CETUXIMAB + RT | N | Y | 330012763 | CETUXIMAB + RT |
| 330003393 | 330006939 | 1.62 | 22.8 | Curative (C) | 2015-09-26 | 2015-10-24 | PAM | 02 | N | 330012766 | MAP |
| 330003394 | 330006939 | 1.57 | 71.8 | Palliative (P) | 2015-06-25 | 2015-06-25 | Cyclophosphamide + Dex + Rituximab | N | N | 330012766 | CYCLOPHOSPHAMIDE + RITUXIMAB |
| 330003395 | 330006939 | 1.9 | 41.4 | Palliative (P) | 2013-09-02 | 2013-09-02 | Cyclophosphamide + Dex + Rituximab | 02 | N | 330012766 | CYCLOPHOSPHAMIDE + RITUXIMAB |
| 330003396 | 330001757 | 1.18 | 90.5 | Palliative (P) | 2014-12-01 | 2014-12-06 | Cisplatin + Etoposide (3 day) | N | N | 330012770 | CISPLATIN + ETOPOSIDE |
| 330003397 | 330001757 | 1.79 | 82 | Neo-adjuvant (N) | 2016-04-08 | 2016-04-10 | OST Euramos 1 Closed Trial - AP | N | N | 330012770 | MAP |
| 330003398 | 330009747 | null | 65.2 | Curative (C) | 2015-06-03 | 2015-06-15 | OST Euramos 1 Closed Trial - AP | N | N | 330012774 | MAP |
| 330003399 | 330001758 | 1.69 | 66 | null | 2017-12-29 | 2018-01-28 | Cetuximab 7 day (Cycle 1) | N | N | 330012775 | CETUXIMAB |
| 330003400 | 330001759 | 1.69 | 82.6 | Neo-adjuvant (N) | null | 2015-11-08 | EW EuroEwing 99 : VIDE | N | N | 330012778 | EURO-EWING |
| 330003401 | 330006941 | 1.6 | 84.5 | Curative (C) | 2017-01-20 | 2017-01-27 | OST Euramos 1 Closed Trial - AP | Y | N | 330012783 | MAP |
| 330003402 | 330009748 | 1.63 | 66 | null | null | 2014-10-13 | DA 3 + 10 | null | null | 330012785 | DA |
| 330003403 | 330001760 | 1.64 | 67.1 | Neo-adjuvant (N) | 2016-08-04 | 2016-08-10 | Dox + HD Mtx (post PAM) | N | N | 330012787 | DOXORUBICIN + HD MTX |
| 330003404 | 330006942 | 1.6 | 32 | Curative (C) | 2015-09-29 | 2015-09-29 | DA 3 + 10 | N | N | 330012793 | DA |
| 330003405 | 330006942 | 1.72 | 92.7 | Neo-adjuvant (N) | 2017-10-02 | 2017-10-07 | EURAMOS TRIAL | N | N | 330012793 | EURAMOS TRIAL |
| 330003406 | 330001761 | 1.72 | 72.2 | null | 2015-09-30 | 2015-10-01 | Carbo F | N | null | 330012799 | CARBO + FLUOROURACIL |
| 330003407 | 330001761 | 1.62 | 85.8 | Palliative (P) | 2017-09-11 | 2017-09-19 | Cisplatin + Etoposide (3 day) | N | N | 330012799 | CISPLATIN + ETOPOSIDE |